morphinans and Seizures

morphinans has been researched along with Seizures* in 22 studies

Other Studies

22 other study(ies) available for morphinans and Seizures

ArticleYear
Effects of the delta opioid receptor agonist KNT-127 on electroencephalographic activity in mice.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:2

    We previously reported that the novel selective delta opioid receptor (DOP) agonist KNT-127 did not cause convulsions in mice, whereas the prototype DOP agonist SNC80 did. Previous studies have reported that SNC80 caused electroencephalographic (EEG) disturbances in rodents. However, whether KNT-127 affects EEG responses is unknown. Therefore, the present study aimed to compare the effect of KNT-127 on EEG responses with that of SNC80 in mice.. For behavioral experiments, male C57BL6/J mice were injected intraperitoneally with either KNT-127 (30 mg/kg) or SNC80 (30 mg/kg) and monitored for convulsions and subsequent catalepsy-like behavior for 10 min immediately after drug treatment. For EEG recording experiments, EEG electrodes were implanted into the right hemisphere. EEG signals exceeding twice the baseline amplitude were defined as seizure spikes.. KNT-127 did not induce convulsive or catalepsy-like behaviors in mice and did not result in seizure spikes, while significantly higher EEG power density was observed at 2 Hz. In contrast, SNC80 administration resulted in convulsive behaviors, seizure spikes, and significantly higher EEG power density between 2 and 10 Hz in mice.. In this study, we clearly demonstrated that KNT-127 administration induces neither convulsive effects nor seizure spikes in mice. We propose that KNT-127 should be considered a candidate compound for the development of improved DOP-based psychotropic drug that lack the convulsive properties.

    Topics: Animals; Behavior, Animal; Benzamides; Electroencephalography; Male; Mice; Mice, Inbred C57BL; Morphinans; Motor Activity; Piperazines; Receptors, Opioid, delta; Seizures

2018
Kappa opioid receptor activation blocks progressive neurodegeneration after kainic acid injection.
    Hippocampus, 2011, Volume: 21, Issue:9

    We recently demonstrated that endogenous prodynorphin-derived peptides mediate anticonvulsant, antiepileptogenic and neuroprotective effects via kappa opioid receptors (KOP). Here we show acute and delayed neurodegeneration and its pharmacology after local kainic acid injection in prodynorphin knockout and wild-type mice and neuroprotective effect(s) of KOP activation in wild-type mice. Prodynorphin knockout and wild-type mice were injected with kainic acid (3 nmoles in 50 nl saline) into the stratum radiatum of CA1 of the right dorsal hippocampus. Knockout mice displayed significantly more neurodegeneration of pyramidal cells and interneurons than wild-type mice 2 days after treatment. This phenotype could be mimicked in wild-type animals by treatment with the KOP antagonist GNTI and rescued in knockout animals by the KOP agonist U-50488. Minor differences in neurodegeneration remained 3 weeks after treatment, mostly because of higher progressive neurodegeneration in wild-type mice compared with prodynorphin-deficient animals. In wild-type mice progressive neurodegeneration, but not acute neuronal loss, could be mostly blocked by U-50488 treatment. Our data suggest that endogenous prodynorphin-derived peptides sufficiently activate KOP receptors during acute seizures, and importantly in situations of reduced dynorphinergic signaling-like in epilepsy-the exogenous activation of KOP receptors might also have strong neuroprotective effects during excitotoxic events.

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; CA1 Region, Hippocampal; Enkephalins; Guanidines; Humans; Interneurons; Kainic Acid; Mice; Mice, Inbred C57BL; Mice, Knockout; Morphinans; Neurodegenerative Diseases; Protein Precursors; Pyramidal Cells; Receptors, Opioid, kappa; Seizures

2011
The role of 5-HT(3) receptors in the additive anticonvulsant effects of citalopram and morphine on pentylenetetrazole-induced clonic seizures in mice.
    Epilepsy & behavior : E&B, 2011, Volume: 21, Issue:2

    Citalopram, a selective serotonin reuptake inhibitor (SSRI), is frequently used in the treatment of major depressive disorders. In addition to its antidepressant features, citalopram shows some anticonvulsive properties at lower doses, whereas higher doses, ingested in cases of suicide, have been associated with seizures. Moreover, some reports support the enhancing effect of morphine on different responses of SSRIs such as analgesic and anticonvulsant properties. Although the exact mechanisms of these additive effects are not yet fully understood, 5-HT(3) receptor has recently been shown to play an important role in the central effects of SSRIs and morphine. In this regard, we used a model of clonic seizures induced by pentylenetetrazole (PTZ) in male NMRI mice to investigate whether morphine and citalopram exhibit additive anticonvulsant effects and, if so, whether this effect is mediated through modulation of 5-HT(3) receptors. In our study, citalopram at lower doses (0.5 and 1 mg/kg, ip) significantly increased the seizure threshold (P<0.01) and at a higher dose (50 mg/kg) had proconvulsive effects. Moreover, morphine at low and noneffective doses had additive effects on the anticonvulsive properties of citalopram. This additive effect was prevented by pretreatment with low and noneffective doses of tropisetron (a 5-HT(3) receptor antagonist) and augmented by 1-(m-chlorophenyl)-biguanide (mCPBG, a 5-HT(3) receptor agonist). Moreover, low doses of morphine (0.1 and 0.5 mg/kg) alone or in combination with potent doses of 5-HT(3) receptor agonist or antagonist could not alter the proconvulsive properties of citalopram at higher dose (50 mg/kg), ruling out the contribution of 5-HT(3) to this effect. In summary, our findings demonstrate that 5-HT(3) receptor mediates the additive anticonvulsant properties of morphine and low-dose citalopram. This could constitute a new approach to augmenting the efficacy and curtailing the adverse effects of citalopram.

    Topics: Analysis of Variance; Animals; Anticonvulsants; Biguanides; Citalopram; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Indoles; Male; Mice; Morphinans; Pentylenetetrazole; Receptors, Serotonin, 5-HT3; Seizures; Serotonin Antagonists; Serotonin Receptor Agonists; Tropisetron

2011
The novel δ opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions.
    Behavioural brain research, 2011, Oct-01, Volume: 223, Issue:2

    We previously reported that the δ opioid receptor (DOP) agonists SNC80 and TAN-67 produce potent antidepressant-like and antinociceptive effects in rodents. However, SNC80 produced convulsive effects. Recently, we succeeded in synthesizing a novel DOP agonist called KNT-127. The present study examined the convulsive, antidepressant-like, and antinociceptive effects of KNT-127 in mice. In contrast to SNC80, KNT-127 produced no convulsions at doses of up to 100mg/kg. In mice subjected to the forced swim test, a screening model for antidepressants, KNT-127 (1mg/kg, s.c.) significantly decreased the duration of immobility and increased the duration of swimming without influencing spontaneous locomotor activity. These behavioral changes were similar to that observed for the tricyclic antidepressant imipramine (6mg/kg). The antidepressant-like effect of KNT-127 in mice was antagonized by pretreatment with naltrindole (NTI), a selective DOP antagonist, or naltriben, a putative DOP(2) subtype antagonist. In addition, KNT-127 (3mg/kg, s.c.) significantly reduced the number of acetic acid-induced abdominal constrictions and the duration of licking time, respectively, in mice subjected to a writhing test and a formalin test. These antinociceptive effects were antagonized by pretreatment with either NTI or 7-benzylidenenaltrexone, a putative DOP(1) subtype antagonist. We propose that KNT-127 should be considered as a candidate compound for the development of DOP-based antidepressants and/or analgesics that lack convulsive effects.

    Topics: Analgesics; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Benzamides; Depression; Dopamine Antagonists; Imipramine; Male; Mice; Mice, Inbred ICR; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Pain Measurement; Piperazines; Receptors, Opioid, delta; Seizures; Swimming

2011
The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.
    British journal of pharmacology, 2005, Volume: 144, Issue:7

    In a previous study, we demonstrated that a dextromethorphan analog, dimemorfan, has neuroprotective effects. Dextromethorphan and dimemorfan are high-affinity ligands at sigma1 receptors. Dextromethorphan has moderate affinities for phencyclidine sites, while dimemorfan has very low affinities for such sites, suggesting that these sites are not essential for the anticonvulsant actions of dimemorfan. Kainate (KA) administration (10 mg kg(-1), i.p.) produced robust convulsions lasting 4-6 h in rats. Pre-treatment with dimemorfan (12 or 24 mg kg(-1)) reduced seizures in a dose-dependent manner. Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. These effects of dimemorfan were comparable to those of dextromethorphan. The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors. We asked whether dimemorfan produces the behavioral side effects seen with dextromethorphan or dextrorphan (a phencyclidine-like metabolite of dextromethorphan). Conditioned place preference and circling behaviors were significantly increased in mice treated with phencyclidine, dextrorphan or dextromethorphan, while mice treated with dimemorfan showed no behavioral side effects. Our results suggest that dimemorfan is equipotent to dextromethorphan in preventing KA-induced seizures, while it may lack behavioral effects, such as psychotomimetic reactions.

    Topics: Animals; Dextromethorphan; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Morphinans; Rats; Rats, Sprague-Dawley; Receptors, sigma; Seizures

2005
Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice.
    Behavioural brain research, 2004, May-05, Volume: 151, Issue:1-2

    A dextromethorphan (3-methoxy-17-methylmorphinan) analog, dimemorfan (3-methyl-N-methylmorphinan) that is not metabolized to dextrorphan [3-hydroxy-17-methylmorphinan, which induces phencyclidine (PCP)-like behavioral effects], attenuates maximal electroshock seizures. However, the pharmacological mechanism of action of dimemorfan remains to be determined. In this study, we assessed the locomotor activity mediated by these morphinans. Circling behavior was pronounced in mice treated with PCP or dextrorphan, while animals treated with dextromethorphan exhibited moderate behaviors. Dimemorfan did not show any significant behavioral effects. We used BAY k-8644 (an L-type Ca2+ channel agonist in the dihydropyridine class) to explore the effects of dextromethorphan and dimemorfan on the convulsant activity regulated by calcium channels. Intracerebroventricular injection of BAY k-8644 (37.5 microg) significantly induced seizures in mice. As with dextromethorphan (6.25 or 12.5 mg/kg), dimemorfan (6.25 or 12.5 mg/kg) pretreatment significantly attenuated BAY k-8644-induced seizures in a dose-dependent manner. BAY k-8644-induced seizure activity paralleled increased expression of c-fos and c-jun, AP-1 DNA binding activity, and fos-related antigen immunoreactivity. Pretreatment with dextromethorphan or dimemorfan significantly attenuated the expression induced by BAY k-8644. Therefore, our results suggest that the anticonvulsant effects of dextromethorphan and dimemorfan are mediated, at least in part, via L-type calcium channel, and that dimemorfan is equipotent to dextromethorphan in preventing BAY k-8644-induced seizures, while it lacks behavioral side effects related to psychotomimetic reactions.

    Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Anticonvulsants; Behavior, Animal; Blotting, Northern; Blotting, Western; Calcium Channels, L-Type; Cell Count; Densitometry; Dose-Response Relationship, Drug; Drug Interactions; Electrophoretic Mobility Shift Assay; Hippocampus; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Morphinans; Motor Activity; Phencyclidine; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Reaction Time; RNA; Seizures

2004
New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice.
    Life sciences, 2003, Mar-07, Volume: 72, Issue:16

    Interest in dextromethorphan (DM) has been renewed because of its anticonvulsant and neuroprotective properties. However, DM at supra-antitussive doses can produce psychotomimetic effects in humans. Recently, we demonstrated that DM exerts psychotropic effects in mice [Neurosci. Lett. 288 (2000) 76, Life Sci. 69 (2001) 615]. We synthesized a series of compounds with a modified morphinan ring system, with the intention of developing compounds that retain the anticonvulsant activity with weak psychotropic effects [Bioorg. Med. Chem. Lett. 11 (2001) 1651]. In order to extend our understanding of the pharmacological intervention of these morphinans, we assessed their behavioral effects, and then examined whether they exert protective effects on maximal electroshock convulsions (MES) in mice. Repeated treatment (20 or 40 mg/kg, i.p./day x 7) with DM or dextrorphan (a major metabolite of DM; DX) significantly enhanced locomotor activity in a dose-related manner. This locomotor stimulation was accentuated more in the animals treated with DX, and might be comparable to that of phencyclidine (PCP). By contrast, treatment with a metabolite of DM [3-methoxymorphinan (3MM) or 3-hydroxymorphinan (3HM)], 3-allyloxy-17-methylmorphinan (CPK-5), or 3-cyclopropylmethoxy-17-methylmorphinan (CPK-6) did not significantly alter locomotor activity or patterns. The behavioral effects mediated by these morphinans and PCP paralleled the effects of conditioned place preference. DM, DX, CPK-5, and CPK-6 had anticonvulsant effects against MES, while 3MM and 3HM did not show any anticonvulsant effects. We found that DM, DX, CPK-5 and CPK-6 were high-affinity ligands at sigma(1) receptors, while they all had low affinity at sigma(2) receptors. DX had relatively higher affinity for the PCP sites than DM. By contrast, CPK-5 and CPK-6 had very low affinities for PCP sites, suggesting that PCP sites are not requisites for their anticonvulsant actions. Our results suggest that the new morphinan analogs are promising anticonvulsants that are devoid of PCP-like behavioral side effects, and their anticonvulsant actions may be, in part, mediated via sigma(1) receptors.

    Topics: Animals; Anticonvulsants; Dextromethorphan; Dose-Response Relationship, Drug; Electroshock; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Morphinans; Radioligand Assay; Receptors, sigma; Seizures

2003
4'-Arylpyrrolomorphinans: effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity.
    Journal of medicinal chemistry, 2002, Jan-17, Volume: 45, Issue:2

    A new method for the preparation of N-benzylpyrrolomorphinans has been developed. Thus Michael reaction of the benzylimines of oxycodones and oxymorphones with nitrostyrenes gave a series of 4'-aryl-N-benzylpyrrolomorphinans. These were selective delta antagonists of much higher in vitro potency (with 5a having K(e) delta = <1 nM) than their binding affinities predicted. In mice in vivo assays 5a showed good delta antagonist activity in the anti-writhing analgesic assay and also inhibited delta agonist-induced convulsant activity.

    Topics: Animals; CHO Cells; Cricetinae; Humans; In Vitro Techniques; Ligands; Male; Mice; Morphinans; Narcotic Antagonists; Radioligand Assay; Receptors, Opioid, delta; Seizures; Structure-Activity Relationship; Transfection; Vas Deferens

2002
Investigation of the involvement of opioid receptors in the action of anticonvulsants.
    Psychopharmacology, 1993, Volume: 111, Issue:4

    This study investigates the possible involvement of opioid receptors in the action of a variety of anticonvulsant agents. The opioid antagonist naloxone (0.3, 1 mg/kg IP) and the selective mu-opioid antagonist cyprodime (3 mg/kg IP) significantly inhibited the increase in electroshock seizure threshold induced by phenytoin (3 mg/kg IP) in mice. The anticonvulsant effects of ethanol (1 g/kg IP) were also significantly antagonised by naloxone (1 mg/kg IP) but not by a 0.3 mg/kg IP dose or by cyprodime (3 mg/kg IP). The results with naloxone were confirmed using higher doses of phenytoin (10 mg/kg IP) and ethanol (1.5 g/kg IP). In contrast to the above findings, naloxone (0.3, 1 mg/kg IP) had no effect on the increase in seizure threshold induced by sodium valproate (200 mg/kg IP) or dizocilpine (MK801, 0.5 mg/kg IP) and paradoxically potentiated the increase in seizure threshold produced by phenobarbitone (15 mg/kg IP); carbamazepine (10 mg/kg IP) and the benzodiazepine agonist loprazolam (1 mg/kg IP), clearly differentiating these compounds from phenytoin and ethanol. These findings suggest that the anticonvulsant effects of phenytoin and ethanol (as assessed by their ability to prevent tonic hindlimb extension in the mouse electroshock model) may be mediated, at least in part, by the release of endogenous opioids and subsequent activation of opioid receptors (mu, in the case of phenytoin, but non-mu, in the case of ethanol) although direct activity at opioid receptors cannot be precluded.

    Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Electroshock; Male; Mice; Mice, Inbred Strains; Morphinans; Naloxone; Narcotic Antagonists; Phenytoin; Receptors, Opioid; Receptors, Opioid, mu; Seizures

1993
Inhibitory influence of morphinans on ictal and interictal EEG changes induced by cortical application of penicillin in rabbits: a comparative study with NMDA antagonists and pentobarbitone.
    Pharmacology, biochemistry, and behavior, 1992, Volume: 43, Issue:2

    The effects of dextrorphan (DX) and dextromethorphan (DM) were tested using the electroencephalogram (EEG) and behavioral effects induced by topical cortical application of penicillin in rabbits. For comparison, the influence of the NMDA antagonists, dizocilpine (MK 801) and 3-((+-(-)2-carboxypiperazine-4-yl)propyl-1-phosphonic acid (CPP), and of pentobarbitone was investigated. Intracortical injection of 500 IU of penicillin produced an EEG spiking followed by a repeated generalization of the electrical and behavioral symptoms. Within a few minutes, DX (5-15 mg/kg, IV) or pentobarbitone (5-10 mg/kg, IV) reduced dose dependently and significantly (p less than 0.01) the interictal and ictal EEG and behavioral effects elicited by cortical injection of 500 IU of penicillin. Higher doses of pentobarbitone (20 mg/kg, IV) but not of DX (20 mg/kg, IV) completely blocked the ictal behavioral and EEG effects elicited by cortical injection of 500 IU of penicillin. Within a few minutes, MK 801 (0.1-0.2 mg/kg, IV) or CPP (10-20 mg/kg, IV) reduced dose dependently and significantly (p less than 0.01) the ictal EEG and behavioral effects elicited by cortical injection of 500 IU of penicillin, while they did not affect the penicillin-induced interictal EEG changes. Higher doses of MK 801 (0.3 mg/kg, IV) completely blocked the ictal behavioral and EEG effects elicited by cortical injection of 500 IU of penicillin. Within a few minutes, DM (10-20 mg/kg, IV) blocked the behavioral effects, but failed to affect either the interictal or the ictal EEG effects induced by cortical injection of 500 IU of penicillin.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Animals; Behavior, Animal; Cerebral Cortex; Dizocilpine Maleate; Electroencephalography; Injections; Male; Morphinans; N-Methylaspartate; Penicillins; Pentobarbital; Piperazines; Rabbits; Receptors, N-Methyl-D-Aspartate; Seizures

1992
Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266.
    Pharmacology & toxicology, 1988, Volume: 62, Issue:3

    The effects of mu-agonists (morphine, fentanyl) and kappa-agonists (U-50,488, U-69,593, bremazocine, nalbuphine, tifluadom) on the electroconvulsive threshold were studied in mice. The threshold could be significantly elevated by all drugs tested in a dose range that was in the order of magnitude of the antinociceptive ED50. Mice tolerant to the antielectroshock effect of morphine still reacted to U-69,593. The antagonism of the anticonvulsant effect by the mu-antagonist naloxone and the kappa-antagonist MR 2266 was receptor-specific only with fentanyl and U-50,488. The other opioid agonists were either antagonized by both drugs (morphine, U-69,593, bremazocine, nalbuphine) or even by the opposite antagonist (tifluadom). A synergistic effect of mu- and kappa-stimulation is assumed for the mediation of the antielectroshock effect of opioid drugs, but drugs with high affinity and intrinsic activity at one receptor type (fentanyl, U-50,488) are obviously able to bring about their antielectroshock effect through the one respective opioid binding site.

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Benzeneacetamides; Benzodiazepines; Benzomorphans; Electroshock; Fentanyl; Male; Mice; Morphinans; Morphine; Nalbuphine; Naloxone; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Seizures

1988
Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices.
    Neuroscience letters, 1988, Feb-29, Volume: 85, Issue:2

    The antitussive, dextromethorphan (DM), and its metabolite, dextrorphan (DX), were evaluated for antiepileptic properties in vitro. Interictal bursts and prolonged ictal epileptiform afterdischarges, induced by perfusion of guinea pig neocortical brain slices with Mg2+-free solution, were blocked by DX (1-250 microM) or DM (100 microM). Intracellular records showed that these agents blocked N-methyl-D-aspartate (NMDA)-induced depolarizations without altering intrinsic membrane properties. DX blocked NMDA but not quisqualate-evoked multi-unit excitatory responses. DM is a widely available, orally effective drug with low toxicity in antitussive doses, which has antiepileptic and NMDA-antagonist properties in vitro. Its toxicity and effectiveness as an anticonvulsant should be expeditiously examined in clinical trials.

    Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Antitussive Agents; Aspartic Acid; Cerebral Cortex; Dextromethorphan; Dextrorphan; Evoked Potentials; Guinea Pigs; In Vitro Techniques; Levorphanol; Morphinans; N-Methylaspartate; Seizures; Valine

1988
[Effects of etorphine and electro-acupuncture on electroconvulsive shock in rats].
    Zhongguo yao li xue bao = Acta pharmacologica Sinica, 1986, Volume: 7, Issue:2

    Topics: Acupuncture Therapy; Animals; Electric Stimulation Therapy; Electroshock; Etorphine; Morphinans; Rats; Seizures

1986
Comparison of the anticonvulsant effects of opioid peptides and etorphine in rats after icv administration.
    Life sciences, 1981, Sep-07, Volume: 29, Issue:10

    Topics: Animals; Anticonvulsants; beta-Endorphin; Dose-Response Relationship, Drug; Endorphins; Enkephalin, Methionine; Enkephalins; Etorphine; Flurothyl; Male; Morphinans; Naloxone; Rats; Rats, Inbred Strains; Seizures; Structure-Activity Relationship

1981
Synthesis and biological activity of fluoroalkylamine derivatives of narcotic analgesics.
    Journal of medicinal chemistry, 1980, Volume: 23, Issue:9

    N-Ethyl-, N-(2-fluoroethyl)-, N-(2,2-difluoroethyl)-, and N-(2,2,2-trifluoroethyl)-substituted normeperidine (1b-e) and normetazocine (2b-e) derivatives were prepared. The analgesic activities of the compounds were determined in mice. Opiate receptor binding studies, in the presence and absence of sodium ion, were carried out. The antagonist activities of normetazocine derivatives were studied in monkeys. These were further examined in the isolated guinea pig ileum for relative agonist activity. The pKa values were measured; in vivo agonist acitivty was lost with weakly basic derivatives. For the normetazocine derivatives, opiate receptor binding data were consistent with guinea pig ileum agonist potency and mouse vas deferens antagonist potency but not with in vivo data. Opiate receptor binding was reduced for the less basic normetazocine derivatives. In the normeperidine series, there was no apparent direct relationship between pKa and opiate receptor binding. However, a relationship involving the hydrophobic character of the N-substituent is discussed. The N-(2-fluoroethyl) derivatives in both series were found to cause convulsions in rats at doses of 40-45 mg/kg ip. Elevated serum citrate levels were found in these rats, implicating in vivo oxidative deamination of the N-(fluoroalkyl) substituent to fluoroacetate.

    Topics: Analgesics, Opioid; Animals; Benzomorphans; Guinea Pigs; Haplorhini; Humans; Male; Meperidine; Mice; Morphinans; Morphine Dependence; Narcotic Antagonists; Rats; Receptors, Opioid; Seizures; Structure-Activity Relationship; Substance Withdrawal Syndrome

1980
Antitussive activity and other related pharmacological properties of d-3-methyl-N-methylmorphinan (AT-17).
    Arzneimittel-Forschung, 1976, Volume: 26, Issue:3

    Antitussive activity and some other related pharmacological properties of d-3-methyl-N-methylmorphinan were studied. Toxic symptoms in mice and dogs were due to the CNS excitation. Acute toxicity of (AT-17) in mice was slightly (s.c.) or far (p.o.) weaker than that of codeine, but it was three times as toxic as codeine in dogs (i.v.). Antitussive efficacy was about 40% of that of codeine in dogs, whereas 77% as potent as codeine in cats. It showed no relaxing effect on the bronchial muscle of guinea pigs in either normal tone or histamine-induced spasms. It had analgesic effect 1/3 as potent as codeine in mice but it was not antagonized by levallorphan. The prolongation of hexobarbital sleeping time by AT-17 was similar extent to that by codeine. Anti-electroshock effect was half as potent as that of phenobarbital. The inhibitory effect on the transportation of intestinal contents in mice was far weaker than that of codeine. Effect on the respiratory and circulatory systems were also investigated.

    Topics: Analgesia; Animals; Antitussive Agents; Blood Pressure; Bronchi; Cats; Codeine; Dextromethorphan; Dogs; Female; Guinea Pigs; In Vitro Techniques; Intestines; Lethal Dose 50; Male; Mice; Morphinans; Muscle Contraction; Muscle Tonus; Rabbits; Respiration; Seizures; Sleep; Trachea; Vasomotor System

1976
Improved synthesis and additional pharmacology of the potent analgetic (-)-5-m-hydroxyphenyl-2-methylmorphan.
    Journal of medicinal chemistry, 1974, Volume: 17, Issue:12

    Topics: Analgesics; Animals; Humans; Lethal Dose 50; Macaca mulatta; Male; Mice; Morphinans; Optical Rotation; Phenols; Seizures; Stereoisomerism; Structure-Activity Relationship; Substance Withdrawal Syndrome; Substance-Related Disorders

1974
The effects of morphine, morphinone and thebaine on the EEG and behavior of rabbits and cats.
    Neuropharmacology, 1971, Volume: 10, Issue:4

    Topics: Animals; Behavior, Animal; Cats; Cerebral Cortex; Depression, Chemical; Electrodes, Implanted; Electroencephalography; Electrophysiology; Female; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Lethal Dose 50; Male; Mice; Mice, Inbred Strains; Morphinans; Morphine; Rabbits; Respiration; Seizures; Stimulation, Chemical; Thebaine

1971
Alcohol dependence and opiate dependence: lack of relationship in mice.
    Science (New York, N.Y.), 1971, Apr-16, Volume: 172, Issue:3980

    According to a recently proposed hypothesis, physical dependence upon alcohol is due to the formation of an endogenous opiate. We tested the hypothesis by determining whether or not ethanol-dependent mice would show typical opiate-dependent behavior (withdrawal jumping syndrome) when challenged with the opiate antagonist naloxone. Our results do not support the hypothesis.

    Topics: Alcoholism; Animals; Dopamine; Ethanol; Humans; Isoquinolines; Male; Mice; Morphinans; Seizures; Substance Withdrawal Syndrome; Substance-Related Disorders

1971
[Analysis of histories of cases of hypoxia during acute poisoning seen at the Hôpital Fernand-Widal].
    Le Poumon et le coeur, 1970, Volume: 26, Issue:8

    Topics: Antidepressive Agents; Barbiturates; Blood Circulation; Carbamates; Carbon Monoxide Poisoning; France; Humans; Hypoxia; Lung Diseases; Morphinans; Phenothiazines; Poisoning; Respiration; Salicylates; Seizures; Trichloroethylene; Vascular Diseases

1970
Inhibition of writhing by narcotic antagonists.
    The Journal of pharmacology and experimental therapeutics, 1966, Volume: 154, Issue:2

    Topics: Analgesics; Animals; Chemical Phenomena; Chemistry; Cyclazocine; Drug Antagonism; Meperidine; Mice; Morphinans; Morphine; Nalorphine; Narcotic Antagonists; Pentazocine; Quinones; Seizures

1966
[THE TOXICITY AND GENERAL PHARMACOLOGICAL ACTIONS OF SINOMENINE].
    Yao xue xue bao = Acta pharmaceutica Sinica, 1963, Volume: 10

    Topics: Alkaloids; Animals; Anura; Apnea; Appetite; Blood Cells; Blood Pressure; Dogs; Dyspnea; Gastrointestinal Tract; Haplorhini; Heart; Hypnotics and Sedatives; Ileum; Mice; Morphinans; Muscle, Smooth; Muscles; Muscular Diseases; Pharmacology; Rabbits; Rats; Research; Seizures; Tachycardia

1963